WASHINGTON (AP) — Sarepta Therapeutics said Tuesday that a patient died while taking its closely watched gene therapy for muscular dystrophy, sending company shares plummeting in morning trading. The young man died of acute liver injury, a known side effect, Sarepta said in a statement. But the company said the “severity” of the patient’s case […]
A patient died from acute liver injury, a known side effect, while receiving Sarepta Therapeutics' Elevidys gene therapy for Duchenne muscular dystrophy, causing Sarepta's shares to drop. This is the first reported death among over 800 patients treated with the therapy, which received FDA approval despite some concerns about its effectiveness. The patient had a recent infection that may have contributed to the liver injury.
